Heron Therapeutics, Inc. re-affirmed earnings guidance for the full year 2024. For the period, Company expects Net Product Revenues of $138.0 million to $158.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | +4.88% | +28.63% | +77.06% |
05-07 | Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
05-07 | Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.06% | 453M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024